Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation (AGEING) - a Feasibility Study

NCT03005236 is registered in ClinicalTrials.gov with University Hospital Birmingham NHS Foundation Trust as lead sponsor.

NCT NCT03005236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03005236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation (AGEING) - a Feasibility Study
Lead sponsor
University Hospital Birmingham NHS Foundation Trust
Phase
Phase 4
Overall status
Unknown status
Start date
April 30, 2017
Completion date
October 31, 2019
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant failure and rejection